Le Lézard
Classified in: Health
Subjects: AWD, NPT

Lymphoma Research Foundation Honors Michael E. Williams, MD with Mantle Cell Lymphoma Leadership Award


NEW YORK, April 8, 2021 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) ? the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services ? presented the inaugural Mantle Cell Lymphoma Leadership Award to Michael E. Williams, MD, Professor of Medicine, and Associate Director for Clinical Affairs at University of Virginia Cancer Center. Dr. Williams was honored during the 2021 LRF Mantle Cell Lymphoma Scientific Workshop on April 7.

Given in recognition of leaders who have worked diligently to advance cures for mantle cell lymphoma (MCL) and improve patient care, the Mantle Cell Lymphoma Leadership Award was presented to Dr. Williams in appreciation of his leadership as the inaugural chair and current member of the LRF Mantle Cell Lymphoma Consortium (MCLC)?composed of 150 international laboratory and clinical scientists whose research is focused on MCL?and his contribution to scientific discoveries in the diagnosis and treatment of MCL.

"Dr. Williams has led the way in advancing our understanding of mantle cell lymphoma," said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. "His contributions to the LRF Mantle Cell Lymphoma Consortium have informed LRF's education programming and resources for patients and led to the growth of the Foundation's MCL research program?making LRF one of the largest private funders of research for this type of lymphoma. We are honored to present Dr. Williams with this award for his dedication to the LRF mission and service to the lymphoma community."

Dr. Michael Williams received his MD from the University of Cincinnati College of Medicine and a Master of Science from the Harvard School of Public Health. He completed his medicine residency and fellowship in hematology/oncology at UVA Health in Charlottesville, VA.

Dr. Williams' research interests are in novel therapeutic approaches for non-Hodgkin lymphomas (NHL), MCL, and chronic lymphocytic leukemia (CLL), including targeted agents and immunotherapies. He serves on the LRF Scientific Advisory Board (SAB) and MCLC and as Co-Chair for the LRF Oral Therapies in Lymphoma and Chronic Lymphocytic Leukemia Scientific Workshop series. He is a member of the European Mantle Cell Lymphoma Network and the Eastern Cooperative Oncology Group Lymphoma Core Committee.

"Many advances in the field of mantle cell lymphoma research have arisen from the Lymphoma Research Foundation's presence in this area, and by their ability to catalyze work with the greatest potential to create an impact on this disease," said Dr. Williams. "I am honored to work with and be recognized by LRF, and look forward to our continued collaboration to drive scientific discovery and improve patients' lives."

The Mantle Cell Lymphoma Leadership Award was presented by LRF MCLC Chair Martin S. Dreyling, MD, PhD of University Hospital LMU Munich at the 2021 MCL Workshop. Since its inception in 2003, the MCL Workshop brings together leading international experts to discuss the latest research findings, foster collaboration within the MCL research community, create new directions for MCL research, and ultimately improve MCL diagnosis and treatment. The annual proceedings paper highlighting key themes and discussions from the MCL Workshop is considered a blueprint for future MCL research and sought out by researchers and clinicians worldwide.

For more information about the LRF Mantle Cell Lymphoma Consortium, Initiative and Workshop, visit lymphoma.org/mclscientificimeetings.

About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded more than $67 million in lymphoma-specific research. For additional information on LRF's research, education and services, visit lymphoma.org.

About UVA Health
UVA Health is an academic health system that includes a 696-bed hospital, the UVA School of Medicine, a level I trauma center, nationally recognized cancer and heart centers and primary and specialty clinics throughout Central Virginia. UVA is recognized for excellence by U.S. News & World Report, Best Doctors in America and America's Top Doctors.

Media Contact

Kinya Harte, Lymphoma Research Foundation, 646-465-9107, [email protected]

Twitter, LinkedIn, Facebook

 

SOURCE Lymphoma Research Foundation


These press releases may also interest you

at 08:45
The "China Non-Invasive Prenatal Testing Market Growth, Share, Size, Trends and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering. This market research report provides key insights into the industry's rapid growth...

at 08:40
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024...

at 08:38
HFA Architecture + Engineering has expanded its healthcare design team with the addition of Principal and Healthcare Practice Leader Paul Sabal (AIA, ACHA, NCARB, LEED AP).  Sabal is a registered architect and interior designer with more than four...

at 08:35
NanoVibronix, Inc. ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...



News published on and distributed by: